Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment
Rhea-AI Summary
Clearmind Medicine (Nasdaq: CMND) reported a Japanese patent application publication for MEAI-based compositions targeting depression, expanding its global intellectual property portfolio. MEAI is a non-hallucinogenic molecule intended as an alternative to SSRIs and psychedelic-based therapies.
The company highlights large and growing anxiety, depression, and broader behavioral health markets, including an estimated $16–22.65 billion global anxiety and depression market in 2025. Japan has about 3 million diagnosed MDD cases. Clearmind is also researching MEAI for alcohol use disorder, metabolic disorders such as weight loss, and other mental health indications.
Positive
- Japanese patent application publication for MEAI-based depression treatment compositions
- IP portfolio spans multiple jurisdictions with multiple granted patents and applications
- Target market for anxiety and depression estimated at $16–22.65 billion in 2025
- Broader behavioral and mental health market projected to approach $350 billion by 2035
- Japan has approximately 3 million diagnosed MDD cases, supporting market opportunity
- MEAI pipeline includes alcohol use disorder and metabolic and other mental disorders
Negative
- None.
News Market Reaction – CMND
In the May 29 session, CMND gained 46.12%, reflecting a significant positive market reaction. Argus tracked a peak move of +94.9% during that session. Our momentum scanner triggered 43 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 8.0x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 26 | Clinical trial advance | Positive | +14.6% | IRB approval at Johns Hopkins to advance CMND-100 Phase I/II trial. |
| May 19 | Reverse share split | Negative | -37.8% | 1-for-10 reverse split to support Nasdaq minimum bid price compliance. |
| May 18 | Preclinical collaboration | Positive | -26.9% | Agreement to study MEAI with tirzepatide in obese mice for weight loss. |
| May 15 | Leadership recognition | Positive | -1.6% | CEO named delegate to federal psychedelic medicine policy summit. |
| May 12 | Clinical milestone | Positive | +3.8% | 20 participants treated in Phase I/IIa CMND-100 trial for AUD. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news often moves the stock sharply, with mixed alignment: positive clinical/IP developments sometimes sell off, while other positive items have triggered strong gains.
Over the last month, CMND has reported several developments, including Phase I/II CMND‑100 trial progress at Johns Hopkins (May 26) and a clinical milestone of 20 treated participants in its AUD trial (May 12). It also executed a 1-for-10 reverse split (May 19) and advanced obesity‑related preclinical work with MEAI and tirzepatide (May 18). Today’s Japanese patent application for MEAI in depression extends the same IP‑driven strategy seen in prior European PTSD filings, reinforcing a pattern of expanding global protections around its neuroplastogen portfolio.
Key Terms
5-methoxy-2-aminoindan medical
selective serotonin reuptake inhibitors medical
ssris medical
major depressive disorder medical
mdd medical
intellectual property regulatory
neuroplastogen medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Vancouver, Canada, May 29, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second-generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the publication of a Japanese Patent Application for its proprietary compositions comprising 5-Methoxy-2-aminoindan (MEAI) for the treatment of depression.
This advancement strengthens Clearmind’s robust intellectual property portfolio, which already includes multiple granted patents and applications worldwide. MEAI, the company’s flagship non-hallucinogenic molecule, is designed to offer a safer, more accessible alternative to traditional antidepressants and emerging psychedelic-based therapies.
Depression remains one of the leading causes of disability worldwide. Current treatments, primarily selective serotonin reuptake inhibitors (SSRIs) and other conventional antidepressants, often come with limitations including delayed onset of action, side effects, and high rates of treatment resistance.
The global market for anxiety and depression treatments is experiencing steady growth. Estimates place the market size at approximately
In Japan, mental health challenges are pronounced due to societal factors such as work-related stress. The country has approximately 3 million diagnosed cases of Major Depressive Disorder (MDD).
Clearmind continues to expand its MEAI-based pipeline, with ongoing research into alcohol use disorder, metabolic disorders such as weight loss, and various other mental disorders. The company’s IP portfolio now spans multiple jurisdictions, reinforcing its position in the rapidly evolving neuroplastogen and mental health therapeutics space.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND."
For further information, visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the expected growth of the global market for anxiety and depression treatments and the behavioral and mental health market and how the Company continues to expand its MEAI-based pipeline, with ongoing research into alcohol use disorder, metabolic conditions, and other mental disorders. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
